ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 0614

Self-Reported Sexual Dysfunction and Perceptions of Rheumatologist Engagement on This Issue in Patients with Systemic Sclerosis
Abstract Number: 2502

Self-Reported Sleep Disorders Among Individuals with Systemic Lupus Erythematosus
Abstract Number: 1346

Semen Analysis of Patients with Psoriatic Arthritis, Axial Spondyloarthritis and Healthy Controls
Abstract Number: 0431

Senescence and Cell Exhaustion in CD4+ and CD8+ Lymphocytes in Rheumatoid Arthritis Patients in Remission Without Treatment
Abstract Number: 0543

Sensitivity of the 2019 European Alliance of Associations for Rheumatology /American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus in a Population-based Cohort; A Study Set in Norway 2000-2015
Abstract Number: 2200

Sensitivity to Change of Structural Outcomes in Early Axial Spondyloarthritis After 10 Years of Follow Up. Data from DESIR Cohort
Abstract Number: 1162

Serial Imaging Changes in Skeletal Muscle Composition and Their Association with Clinical Outcomes in Idiopathic Inflammatory Myopathies
Abstract Number: 1227

Serious Infections Following Rituximab Administration in Children with Systemic Lupus Erythematosus
Abstract Number: 0415

Serious Infections Hospital Admissions and Mortality in Patients with Early Inflammatory Arthritis: Results from a Large UK Cohort
Abstract Number: 1064

Seroconversion Rates in Rituximab-Treated Rheumatic Patients Receiving COVID-19 Vaccination
Abstract Number: 0060

Serpin B1 Modulation of Immune Complex-Mediated Neutrophil Activation and NET-formation Requires Its Chymotrypsin-like Inhibitory Activity
Abstract Number: 2119

Serum Alarmin Concentrations and Risk of Incident Major Adverse Cardiovascular Events and Heart Failure in a Multicenter, Prospective Rheumatoid Arthritis Cohort
Abstract Number: 2140

Serum Alarmins and the Risk of Interstitial Lung Disease in Patients with Rheumatoid Arthritis
Abstract Number: 0553

Serum Isolevuglandin IgG Antibody Concentrations Are Increased in Patients with Systemic Lupus Erythematosus versus Control Subjects and Associated with Lower 24-hour Blood Pressure
Abstract Number: 0113

Serum Myeloperoxidase (MPO)-DNA Complexes and Serum Calprotectin Differentiate Isolated Thrombotic Antiphospholipid Syndrome from Isolated Obstetric Antiphospholipid Syndrome

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].